Cantor Fitzgerald Has Weak Forecast for FDMT FY2025 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a research note issued to investors on Tuesday, November 11th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings of ($3.70) per share for the year, down from their previous forecast of ($3.60). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for 4D Molecular Therapeutics’ FY2026 earnings at ($2.60) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.01. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%.

Other research analysts also recently issued reports about the stock. Barclays decreased their target price on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday. Leerink Partners reissued an “outperform” rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Roth Capital decreased their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Chardan Capital lifted their target price on 4D Molecular Therapeutics from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Royal Bank Of Canada boosted their price objective on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an “outperform” rating in a research report on Tuesday. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $28.70.

4D Molecular Therapeutics Price Performance

FDMT stock traded down $0.25 during mid-day trading on Thursday, reaching $10.72. 103,297 shares of the company traded hands, compared to its average volume of 857,287. The company has a market capitalization of $500.74 million, a P/E ratio of -2.86 and a beta of 2.96. 4D Molecular Therapeutics has a 52-week low of $2.23 and a 52-week high of $12.34. The company has a fifty day moving average price of $9.18 and a 200-day moving average price of $6.18.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new stake in 4D Molecular Therapeutics in the first quarter valued at approximately $41,000. Proficio Capital Partners LLC grew its holdings in 4D Molecular Therapeutics by 26.0% during the 1st quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company’s stock valued at $75,000 after buying an additional 5,195 shares during the last quarter. Federated Hermes Inc. lifted its holdings in 4D Molecular Therapeutics by 33,131.8% in the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock valued at $4,038,000 after purchasing an additional 1,246,419 shares in the last quarter. Privium Fund Management B.V. raised its position in shares of 4D Molecular Therapeutics by 8.3% in the 1st quarter. Privium Fund Management B.V. now owns 131,000 shares of the company’s stock worth $423,000 after buying an additional 10,000 shares during the period. Finally, Invesco Ltd. lifted its position in 4D Molecular Therapeutics by 318.3% during the 1st quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock worth $380,000 after acquiring an additional 89,611 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

Insider Activity

In other news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the sale, the insider owned 3,594 shares of the company’s stock, valued at approximately $43,128. The trade was a 42.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 9,128 shares of company stock valued at $92,100 in the last ninety days. 9.60% of the stock is owned by corporate insiders.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.